



## Press Release

---

**SYNLAB International GmbH**

Moosacher Straße 88

80809 Munich

Germany

Munich, 4 April 2024

### **SYNLAB launches bipolar disorder diagnostic test myEDIT-B in France**

- myEDIT-B is the world's first clinically validated test for the differential diagnosis between bipolar disorder and unipolar depression
- myEDIT-B reduces time to diagnosis of bipolar disorder within 4 weeks from the blood drawn, expediting the process from 8 years on average - available on prescription at SYNLAB France starting April 2024\*

SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, is marking World Bipolar Day 2024 by announcing the launch of a revolutionary test for the diagnosis of bipolar disorder in France. myEDIT-B is the first clinically validated test for the differential diagnosis between bipolar disorder and unipolar depression, signalling a paradigm shift in the identification of this mental health disorder and thus increasing the effectiveness of the treatment approach.

Technically, myEDIT-B measures RNA editing changes of specific markers in patients' blood. SYNLAB uses cutting-edge Next Generation Sequencing (NGS) technology with a unique algorithm developed by ALCEDIAG for this test.

myEDIT-B is the product of a collaboration between diagnostics manufacturer ALCEDIAG and SYNLAB, carried out within the framework of the EU funding programme EIT Health. The innovative test is also available in Italy since October 2023.

After excellent performance in two clinical studies, myEDIT-B has obtained CE-IVD marking. Furthermore, SYNLAB and ALCEDIAG will begin a study in May involving several hospitals and psychiatric institutions across France to underpin the clinical utility of the test, driving positive patient outcomes and medical excellence. The study has been awarded 1.4 million Euro in funding from the French government as part of the France 2030 Programme administrated by the French Bank of Public Investments (BPI). This financing has been obtained following a rigorous selection process conducted by BPI.

*"SYNLAB makes innovative medical diagnostic services quickly available for patients and medical professionals. On World Bipolar Day 2024, we are particularly pleased to launch myEDIT-B in France, initiating new professional relationships with psychiatrists and psychiatric care facilities. The availability*

---

\* Details and terms of use can be found here: <https://www.synlab.fr/sante-mentale/depression-et-troubles-bipolaires/>



*of myEDIT-B in France is a major step forward for patients and demonstrates our passion for medical excellence. It also underscores the value that medical diagnostics and specialty testing bring to the field of psychiatry,"* said Mathieu Floreani, CEO of SYNLAB Group.

– Ends –

**For more information:**

<b>SYNLAB</b> Diana Tabor, FTI Consulting	+49 (0) 69 9203 7153 <a href="mailto:Diana.Tabor@fticonsulting.com">Diana.Tabor@fticonsulting.com</a>
--	--

**About SYNLAB**

- SYNLAB Group is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments, and corporates.
- Providing the leading level of service within the industry, SYNLAB is the partner of choice for routine and specialty diagnostics in human and veterinary medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
- SYNLAB operates in more than 30 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy. More than 27,000 employees, including over 2,000 medical experts, contribute every day to the Group's worldwide success.
- SYNLAB performed around 600 million laboratory tests and achieved revenues of €2.64 billion in 2023. Ticker symbol: SYAB; ISIN: DE000A2TSL71
- More information can be found on [www.synlab.com](http://www.synlab.com)

**Forward looking statements**

This document does not constitute or form a part of, and should not be construed as, an offer for sale or subscription of or solicitation of any offer to purchase or subscribe for any securities in any jurisdiction.

Statements made in this document may include forward-looking statements. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words "believes", "expects", "expected", "may", "will", "would", "should", "seeks", "pro forma", "anticipates", "intends", "plans", "estimates", "estimated", or the negative of any thereof or other variations thereof or comparable terminology, or by discussions of strategy or intentions. These statements are not guarantees of future actions or performance and involve risks, uncertainties and assumptions as to future events that may not prove to be accurate. Actual actions or results may differ materially from what is expressed or forecasted in these forward-looking statements. As a result, these statements speak only as of the date they were made and SYNLAB undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. It should be noted that past performance is not a guide to future performance. Interim results are not necessarily indicative of full-year results.